Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/First Tracks Biotherapeutics, Inc./ EFFECT

Notice of Effectiveness · EFFECT

First Tracks Biotherapeutics, Inc.

TRAXNASDAQEQUITYCurrent

Notice of Effectiveness

Filed Oct 29, 2026Accepted Oct 30, 2026, 12:15 AM EDTFiling CIK 2091349Accession 9999999995-26-003380
View company →Permanent SEC source ↗
Share

Structured filing — EFFECT

primary_doc.xml

Open full document ↗

Notice details

Submission type
EFFECT
Act
33

Effectiveness

Effective date
2026-10-29
Effective time (as filed)
16:00:00
Form
S-1

Registrant 1

Registrant
First Tracks Biotherapeutics, Inc.
Registrant CIK
0002091349
File number
333-299632

Company context

We are a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Our pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a blood dendritic cell antigen 2 (“BDCA2”) modulator.

Current securities

TRAXNASDAQ · EQUITY · Current

Recent company filings

  1. SCHEDULE 13G - filed by Adage Capital Management, L.P. regarding First Tracks Biotherapeutics, Inc.Nov 12, 2026
  2. SCHEDULE 13G/A - filed by FMR LLC regarding First Tracks Biotherapeutics, Inc.Nov 6, 2026
  3. 424B3 filingNov 4, 2026
  4. 424B3 filingNov 4, 2026
  5. 4 filingNov 3, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.